Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Dianthus Therapeutics (DNTH) Non Operating Income: 2022-2025

Historic Non Operating Income for Dianthus Therapeutics (DNTH) over the last 3 years, with Sep 2025 value amounting to $3.5 million.

  • Dianthus Therapeutics' Non Operating Income fell 25.45% to $3.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $14.0 million, marking a year-over-year decrease of 11.69%. This contributed to the annual value of $16.9 million for FY2024, which is 265.77% up from last year.
  • As of Q3 2025, Dianthus Therapeutics' Non Operating Income stood at $3.5 million, which was up 6.82% from $3.3 million recorded in Q2 2025.
  • In the past 5 years, Dianthus Therapeutics' Non Operating Income registered a high of $4.7 million during Q3 2024, and its lowest value of $470,000 during Q3 2022.
  • For the 3-year period, Dianthus Therapeutics' Non Operating Income averaged around $2.9 million, with its median value being $3.5 million (2024).
  • Its Non Operating Income has fluctuated over the past 5 years, first soared by 622.80% in 2024, then declined by 28.26% in 2025.
  • Quarterly analysis of 4 years shows Dianthus Therapeutics' Non Operating Income stood at $577,000 in 2022, then surged by 314.73% to $2.4 million in 2023, then spiked by 45.26% to $3.5 million in 2024, then decreased by 25.45% to $3.5 million in 2025.
  • Its last three reported values are $3.5 million in Q3 2025, $3.3 million for Q2 2025, and $3.7 million during Q1 2025.